Stryker Corporation (NYSE:SYK) Position Lowered by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lowered its position in Stryker Corporation (NYSE:SYK - Free Report) by 0.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,174,298 shares of the medical technology company's stock after selling 4,836 shares during the quarter. Stryker comprises about 4.0% of Loring Wolcott & Coolidge Fiduciary Advisors LLP MA's holdings, making the stock its 6th biggest holding. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA owned approximately 0.31% of Stryker worth $419,354,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Stryker during the 4th quarter worth about $25,000. Capital A Wealth Management LLC acquired a new stake in shares of Stryker during the fourth quarter valued at about $26,000. Rakuten Securities Inc. raised its stake in shares of Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after acquiring an additional 68 shares during the period. City Holding Co. raised its stake in shares of Stryker by 528.6% in the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company's stock valued at $33,000 after acquiring an additional 74 shares during the period. Finally, VSM Wealth Advisory LLC acquired a new position in shares of Stryker in the 4th quarter worth approximately $36,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director now directly owns 3,417,326 shares of the company's stock, valued at $1,288,195,208.96. The trade was a 5.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 5.90% of the stock is currently owned by insiders.

Stryker Stock Performance

Shares of SYK stock opened at $390.67 on Friday. The company has a market cap of $149.11 billion, a P/E ratio of 52.79, a PEG ratio of 2.96 and a beta of 0.91. The firm has a fifty day moving average price of $378.06 and a 200 day moving average price of $375.38. The company has a current ratio of 1.64, a quick ratio of 1.00 and a debt-to-equity ratio of 0.69. Stryker Corporation has a 12 month low of $314.93 and a 12 month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.73 by $0.11. Stryker had a return on equity of 23.74% and a net margin of 12.31%. The business had revenue of $5.87 billion during the quarter, compared to analysts' expectations of $5.68 billion. During the same period in the prior year, the firm posted $2.50 EPS. The business's quarterly revenue was up 11.9% compared to the same quarter last year. Sell-side analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. Stryker's dividend payout ratio (DPR) is presently 45.41%.

Wall Street Analyst Weigh In

SYK has been the subject of several research reports. Needham & Company LLC reiterated a "buy" rating and issued a $442.00 target price on shares of Stryker in a report on Friday, March 21st. Wall Street Zen upgraded Stryker from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th. Evercore ISI dropped their price objective on Stryker from $400.00 to $390.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. The Goldman Sachs Group set a $422.00 target price on Stryker in a research note on Tuesday, March 4th. Finally, BTIG Research set a $403.00 target price on Stryker and gave the company a "buy" rating in a research report on Monday, April 14th. Four analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $427.30.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.